Trial Profile

A Phase 1/2a, Open-Label, Dose Escalation and Expansion Study of the Safety and Tolerability of T3011 Administered Via Intratumoral Injection as a Single Agent and in Combination With Intravenous Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 15 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary) ; T 3011 (Primary)
Indications Head and neck cancer; Malignant melanoma; Mesothelioma; Non-small cell lung cancer; Sarcoma; Solid tumours
Focus Adverse reactions; First in man
Sponsors Immvira Pharma

08 Oct 2025 Planned number of patients changed from 64 to 30.
08 Oct 2025 Planned End Date changed from 31 Oct 2025 to 10 Jan 2027.
08 Oct 2025 Planned primary completion date changed from 31 Oct 2023 to 22 Sep 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com